To the Editor: Due to the risks of radiation exposure associated with conventional fluoroscopy,\[[@ref1]\] ultrasonography is gradually replacing it in our hospital for percutaneous closure of congenital heart defects. Ultrasound-guided percutaneous closure of congenital heart defects is mostly used for young children; therefore, safe and effective anesthetic management is needed. Here, we report a rare case of transesophageal echocardiography (TEE)-guided percutaneous closure of an atrial septal defect (ASD) in an infant under high-dose dexmedetomidine sedation without endotracheal intubation.

A 2-year-old girl (weight, 13 kg) was scheduled to undergo transthoracic echocardiography (TTE)-guided percutaneous closure of an ASD. The patient fasted for the standard period of time and received no preanesthetic medication. After entering the operating room, the patient was monitored by electrocardiogram, noninvasive blood pressure measurement, and pulse oximetry. Anesthesia was induced with intravenous ketamine 1 mg/kg plus midazolam 0.1 mg/kg. Sevoflurane was then administered via a face mask. When the patient\'s end-tidal sevoflurane reached 2.0 minimum alveolar concentration, a laryngeal mask airway was inserted. Anesthesia was maintained using a continuous intravenous infusion of dexmedetomidine, supplemented with 1% inhaled sevoflurane. The loading dose of dexmedetomidine was 1 μg/kg with the infusion rate at 50 μg/h, after which the infusion rate of dexmedetomidine was titrated according to the patient\'s response to pain and the patient\'s heart rate. During the ASD closure, the sonographer noted that the patient\'s TTE image was unclear and suggested that TEE was needed to provide adequate ultrasound guidance. The interventional cardiologist suggested that anesthetic management without general anesthesia and endotracheal intubation would be preferable. Thus, the anesthesiologist used an unconventional anesthetic technique with dexmedetomidine as the sole sedative agent. As the sevoflurane was discontinued and the laryngeal mask airway was removed, the dexmedetomidine infusion rate was increased to 100 μg/h, and oxygen was administered via a face mask beside the nose of the patient using the anesthesia circuit. When the patient\'s heart rate decreased from 100 beats/min to 90 beats/min, the sonographer successfully inserted the pediatric TEE probe, and the dexmedetomidine infusion rate was decreased to 15 μg/h. The duration of TEE guidance was 6 min, during which time the patient did not move or cough, and her vital signs and oxygen saturation remained stable. At the end of the procedure, the infusion of dexmedetomidine was stopped, and the patient was transferred to the Pediatric Intensive Care Unit where she recovered 1 h later. The patient was discharged home 2 days later without complication.

This case is unique because it required TEE guidance due to unclear TTE imaging during the percutaneous closure of an ASD in an infant. According to the literature, the need for TEE during percutaneous closures of congenital heart defects is rare and is typically limited to obese adults.\[[@ref2]\] The technical advantages of ultrasound guidance over fluoroscopy guidance in infants are diminished if the patient is intubated. Therefore, interventional cardiologists prefer anesthetic management without general anesthesia and endotracheal intubation in this case.

According to a previous study, the TEE probe generally does not obstruct the airway or disrupt spontaneous breathing in children.\[[@ref3]\] Ideal sedative drugs enable infants to tolerate the stimulation due to TEE probe insertion without causing respiratory depression and/or hemodynamic instability. Although propofol has been recognized for use during adult TEE examination without endotracheal intubation,\[[@ref4]\] further evidence is needed before this drug is widely applied to infants.

Dexmedetomidine is a highly selective α2-adrenergic agonist. Unlike other sedatives, such as propofol, dexmedetomidine can effectively sedate patients without causing respiratory depression. Dexmedetomidine was approved in 1999 by the U.S. Food and Drug Administration for use as a short-term sedative and analgesic agent. Although it has not been reported in the literature, we suggest that dexmedetomidine can be used to safely sedate infants undergoing TEE-guided percutaneous closure of congenital heart defects, as the use of this drug can preserve spontaneous breathing and avoid the need for endotracheal intubation. In the present case, the time it took to achieve the required depth of sedation was shortened using a high initial infusion rate of dexmedetomidine, which caused no significant hemodynamic changes different from those descriptions in the literature.\[[@ref5]\] The decrease in heart rate can be considered as the best clinical indicator of the onset of dexmedetomidine sedation. In addition, this case showed once again that high-dose dexmedetomidine was able to achieve satisfactory sedative and analgesic effects in an infant without causing respiratory depression.

With the increased popularity of ultrasound-guided percutaneous closure of congenital heart defects, it is likely that other infants will require TEE during these procedures in the future. Although endotracheal intubation is generally preferred for securing the airway during general anesthesia, the present case indicates that dexmedetomidine can be used to safely sedate infants undergoing ultrasound-guided percutaneous closure of congenital heart defects without the need for endotracheal intubation. Further studies are needed to validate the findings of this case.
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